CDK2-IN-12

• Description:

  CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity[1].

• UNSPSC:

  12352005

• Target:

  Carbonic Anhydrase; CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk2-in-12.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(C1=CC=C(/N=N/C2=C3N=C(C4=CC=C(C)C=C4)C(C#N)=C(N)N3N=C2N)C=C1)(N)=O

• Molecular Formula:

  C20H17N9O2S

• Molecular Weight:

  447.47

• References & Citations:

  [1]Said MA, et al. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation. Eur J Med Chem. 2020 Mar 1;189:112019.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CA II; CA IX; CDK2; CDK9

• CAS Number:

  [2410402-88-7]